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taken from the 2005 National Inpatient Sample. One-way frequencies, summary sta-
tistics, table analysis, logistic regression, linear regression, and kernel density were all 
used to evaluate the data. We used exploratory data analysis to investigate patient 
outcomes. There were 5622 patients with pneumonia and a control group of 5600
patients. RESULTS: Pneumonia affects 1–2 year olds more than older children. Most 
of the patients had a Charlson number of 0, indicating non-severe conditions. Out of 
5622 patients, there were 73 fatalities. The majority of patients had a hospital expense
of $2,000 to $12,000. Sex did not play a huge factor in the distribution of patient
deaths. The mean age was 7.29 years old. The mean length of stay was 9.41 days. 
Patient procedure and diagnosis codes were analyzed to discover which codes had the
most signiﬁ cant impact on patients, length of stay, and total hospital charges. Patients
with additional diseases were analyzed to see if there was a signiﬁ cant difference in
hospital length of stay and total hospital charges. CONCLUSIONS: Patients have 
different hospital costs, lengths of stay, initial diagnosis, procedures and outcomes
according to their sickness, and how they can be treated. Most patients that come into
the hospital do not have to stay too long, have a moderate hospital expense, and are
generally young children. Pneumonia is a serious illness, occasionally fatal, but it can
usually be treated successfully.
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OBJECTIVES: The primary objective is to compare candidemia treatment success
between micafungin and caspofungin. Secondary objectives are to identify cost and
mortality rates associated with the use of micafungin versus caspofungin. METHODS:
This was a retrospective chart review of patients who received one dose of micafungin 
or caspofungin during their hospitalization in a regional VA medical center between
January 1, 2004 and February 29, 2008. A combination of electronic data extraction
and manual chart review was performed on each subject’s medical record for patient
characteristics, risk factors, antifungal use prior and post echinocandin, adverse drug
reactions associated with echinocandins, microbiological eradication, clinical success,
length of stay, total hospital cost, and echinocandin cost. All statistical tests were
two-tailed with p-value of less than 0.05 considered statistically signiﬁ cant. RESULTS:
A total of 106 patients with at least one positive bloodstream or sputum culture for 
C. albicans or C. non-albicans were included. Treatment groups had similar baseline
characteristics in all areas except more micafungin patients had renal failure (p 
0.016), prior antifungal use (p  0.021) and post antifungal use (p  0.002). Treatment 
success rates were comparable among groups (74% micafungin compared to 64% 
caspofungin, p  0.279). Microbiological success was 54% vs. 45% (p  0.367) for 
micafungin vs. caspofungin, respectively. There was no difference in microbiological
success between C. albicans and C. non-albicans for micafungin (p  0.802), however, 
a signiﬁ cant difference was seen in the caspofungin patients (C. albicans 35% vs. 59% 
C. non-albicans, p  0.05). Total cost of patient care (p  0.027) and echinocandin 
overall cost (p  0.001) were signiﬁ cantly lower in the micafungin group. Length of 
stay and mortality rates were comparable among groups. CONCLUSIONS: We found
overall treatment success was non-inferior among micafungin and caspofungin 
therapies.
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OBJECTIVES: Achieving sustained virologic response (SVR) could prevent further
transmission of hepatitis C virus (HCV) and reduce chronic hepatitis C (CHC) inci-
dence; we developed a compartment model to describe the dynamics of HCV transmis-
sion in the United States. METHODS: This population model was expressed by partial
differential equations across compartments based on: injection-drug use, CHC infec-
tion, diagnosis, genotypes, treatment/re-treatment, SVR and disease progression.
Model inputs were based on published sources. Model was calibrated from 2002–
2006 and matched closely with CDC reports and other published literature. The cali-
brated model was then applied to assess the CHC burdens from 2007–2040 under 
the current pegylated-interferon/ribavirin (P/R) treatment strategy. A scenario from a
hypothetical new CHC regimen (NEW) was also assessed. This included: NEW avail-
able in 2011 (70% SVR) for genotype-1, treatment-naïve patients; P/R treatment-
failure patients (TFs) re-treated by NEW with 50% SVR; NEW not used to treat
genotype-2/3 patients; P/R durations consistent with current treatment guidelines by
genotypes and costs $28,000/48-week; diagnosis and treatment rates remain unchanged
with NEW. All costs were converted into 2007 dollars using 3% discount rate. 
RESULTS: Under P/R, US CHC prevalence at 2040 is projected to be around 1.7 
million. Overall CHC direct medical cost is about $6 billion a year under P/R, only
13% of which is treatment-related; the remaining 87% comes from managing the
comorbidities and long-term consequences of advanced liver disease (ALD) among 
undiagnosed patients, diagnosed-but-never-treated patients, and TFs. Compared to
P/R, NEW is projected to cure 351,448 more patients, prevent 23,444 more CHC
incidences, avert 103,953 more ALD incidence, and prevent 39,929 more deaths from 
2007–2040. CHC prevalence at 2040 under NEW is projected to be 335,000 fewer 
patients. CONCLUSIONS: A new CHC regimen may have a higher public health 
impact than P/R. Costs unrelated to current CHC treatment with P/R are the major 
burden of hepatitis C.
PIN5
PHARMACOGENOMICS: APPLICABILITY IN ANTIRETRO VIRAL THERAPY 
(ART) IN HIV PATIENTS
Goyal R1, Rai MK1, Chawla A2, Siddiqui MK2, Srivastava K2
1Heron Health Private Limited, Plot No 22-23, Rajiv Gandhi IT Park, Chandigarh, India, 
2Heron Health Private Limited, Chandigarh, India
OBJECTIVES: The objective of the study was to explore the applicability of pharma-
cogenomics in ART (Antiretro viral therapy). METHODS: Pharmacogenomic studies
in HIV patients were identiﬁ ed from the database of WHO, Pubmed, Clinical trials.
gov and relevant grey literature from 2000–2008. Two reviewers independently 
extracted data. RESULTS: Pharmacogenomics provides a powerful support to inves-
tigate variable responses to antiretroviral therapy. To date, few antiretrovirals appear 
to have a clear genotype–phenotype correlation. However, such correlations have
been demonstrated for CYP2B6 and efavirenz disposition, HLA-B*5701 and abacavir 
hypersensitivity, and UGT1A1 and atazanavir hyperbilirubinemia. Clinically signiﬁ -
cant and conﬁ rmed pharmacogenomic relationships were identiﬁ ed for three ART 
drugs. Out of 405 studies, 6/202 studies were identiﬁ ed as relevant to CYP2B6 and
efavirenz disposition (2RCTs, 1 nRCT and 3 pharmacokinetic studies). Three (3/118) 
studies were identiﬁ ed for HLA-B*5701 and abacavir hypersensitivity (2 RCTs and 1
nRCT) and 2/85 studies for UGT1A1 and atazanavir hyperbilirubinemia (1RCT and 
1nRCT). Studies (2/6) revealed that genotype and sex were identiﬁ ed as predictive 
covariates of efavirenz disposition. Studies (2/3) across the world have consistently 
demonstrated that HLA-B*5701 predicts the likelihood of hypersensitivity reactions
to abacavir. As a consequence, pharmacogenetic screening for HLA-B*5701 has
entered routine clinical practice and is recommended in most guidelines before starting 
an abacavir containing regimen. Studies (1/2) show that polymorphisms at MDR1-
3435 signiﬁ cantly inﬂ uence atazanavir plasma concentrations, although ATV plasma 
concentrations directly correlate with bilirubin levels, the risk of severe hyperbilirubi-
nemia is further increased in the presence of the UGT1A1-TA7 allele. CONCLU-
SIONS: Although the wider applicability of pharmacogenomic relationships is 
prevalent and its use in clinical practice is still limited. Pharmacogenomics can greatly 
contribute in taking more adequate therapeutic decisions and to optimise treatment 
for HIV/AIDS.
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OBJECTIVES: The human papillomavirus is the most common sexually transmitted 
disease in America. This virus will affect 6.2 million Americans this year. Most cases 
of HPV come from sexual contact or vaginal delivery from an infected mother. It is the 
objective of this study to gain more knowledge about HPV in order to be able to control
or prevent the spreading of this virus. METHODS: A data set of over 22,000 pediatric
patients from the 2005 National Inpatient Sample was used for analysis with SAS 
Enterprise Guide to examine different characteristics of HPV. From SAS, we were able 
to set up one way frequencies, pie charts, kernel densities, and logistic and linear
regressions to compare and contrast different aspects of HPV. We also examined patient 
diagnosis and procedure codes. RESULTS: The most prominent age groups affected 
by HPV are young children and adolescents. This is a concern since there is a strong 
relationship to cervical cancer in later life. Although two types of the virus (16 and 18)
are responsible for 70% of cervical cancers, less than 1% of the patients in our sample 
died with HPV. This virus is not costly to detect or treat with the majority of the patients 
charged around $5,000 from hospitalization with the virus. We found that 90% of 
patients with a URI also had HPV. We found many statistically signiﬁ cant relationships 
between demographics, procedures, and diagnoses, and length of stay or total charges 
of the patient. CONCLUSIONS: Further research is still needed for doctors to be able 
to prevent or cure HPV. Trial medications are out on the market targeting young
females, but surprisingly, more males have HPV because they are the carriers of this 
virus. We need to focus more time and money to ﬁ nd a cure for HPV.
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OBJECTIVES: Cellulitis is a skin infection caused by bacteria. In children, cellulitis 
most often occurs on the face, legs, arms, or around the area near the anus. It can 
usually be treated with antibiotics (oral or topical). However, if not treated, the infec-
tion can spread and cause far more serious conditions such as meningitis or blood clots
in the legs. The objective of this paper is to explore the data of pediatric patients who 
have cellulitis and to compare the results to patients who do not have the disease. Basic
variables such as age, race, and gender are examined along with recorded patient 
diagnosis and procedure codes. METHODS: The statistical software SAS was used to
analyze and explore the data supplied by the National Inpatient Sample for 2005. The
dataset contained 1287 patients with cellulitis and a control group of 1300 without 
cellulitis. Statistical methods used include one-way frequencies, kernel densities,
summary statistics, table analyses, logistic regression, and linear regression. We also 
examined the most frequent patient diagnoses and procedures for the patients in the 
dataset. RESULTS: The patients represented by the data are all pediatric. About 63% 
of patients with cellulitis are male, with about 37% female. The age group with the 
highest concentration of patients is 0–3 with about 29% of the total. Only 0.08% of 
the patients with cellulitis actually died. In general, the disease is not fatal. The average 
